Skip to content
Search

Latest Stories

NPA chief executive Mark Lyonette to retire next year

The National Pharmacy Association (NPA) has announced the retirement of its Chief Executive, Mark Lyonette.

Mark will retire in 2024. The association has announced his retirement well in advance so that the Board can start work with a leading recruitment agency to search for the new Chief Executive.


“The Board is keen to build on the strong foundations established and ensure there is a seamless transition and minimum disruption to the business once the new Chief Executive is in post,” said the association.

Mark said: “After five years at the NPA and 40 years working for and leading national membership organisations, I am looking forward to living a different life.

“I am pleased that in the time that I have been with the NPA we have grown both the membership and customer base and created a profitable, stable membership organisation.

“Alongside our NPA Insurance company, the association is well set to help members face the future.

“Meanwhile there is much to do to ensure that 2023 is another good year in terms of the NPA delivering consistently for members. The process of changing Chief Executive won’t deflect us from our vital work.”

Outgoing Chair of the Board, Andrew Lane, said: “By the time he steps down Mark will have been with us for five years and I am pleased to have worked with him for the last four of those years as Chair. In that time the NPA has gone from strength to strength and introduced important new services for members, as well as vigorously advocating for a sustainable future for our sector.

“Together Mark and I had the honour of leading the organisation through the pandemic, campaigning tirelessly for members while also building much needed trust with government and stakeholders.

“It’s probably too early yet to say this, but on behalf of the Board we wish Mark all the best for a well-earned retirement when it comes.”

Over the next few weeks, the NPA Board will agree what the future chief executive role looks like, advertise the role and start the search process.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less